171 related articles for article (PubMed ID: 31912791)
21. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
22. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
23. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
24. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
Ascierto PA; Ribas A; Larkin J; McArthur GA; Lewis KD; Hauschild A; Flaherty KT; McKenna E; Zhu Q; Mun Y; Dréno B
J Transl Med; 2020 Aug; 18(1):294. PubMed ID: 32746839
[TBL] [Abstract][Full Text] [Related]
25. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
Livingstone E; Gogas H; Kandolf-Sekulovic L; Meier F; Eigentler TK; Ziemer M; Terheyden PAM; Gesierich AH; Herbst RA; Kähler KC; Ziogas DC; Mijuskovic Z; Garzarolli M; Garbe C; Roesch A; Ugurel S; Gutzmer R; Grob JJ; Kiecker F; Utikal J; Windemuth-Kieselbach C; Eckhardt S; Zimmer L; Schadendorf D
Eur J Cancer; 2023 Sep; 190():112941. PubMed ID: 37482012
[TBL] [Abstract][Full Text] [Related]
26. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
[TBL] [Abstract][Full Text] [Related]
27. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib in Chinese patients with BRAF
Si L; Zhang X; Xu Z; Jiang Q; Bu L; Wang X; Mao L; Zhang W; Richie N; Guo J
BMC Cancer; 2018 May; 18(1):520. PubMed ID: 29724167
[TBL] [Abstract][Full Text] [Related]
29. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Escudier B; Gerletti P; Li S; Casey M; Laguerre B; Pandha HS; Pantuck AJ; Patel A; Lechuga MJ; Ravaud A
Clin Cancer Res; 2018 Apr; 24(7):1554-1561. PubMed ID: 29374054
[No Abstract] [Full Text] [Related]
30. Vemurafenib in non-small-cell lung cancer patients with BRAF
Mazieres J; Cropet C; Montané L; Barlesi F; Souquet PJ; Quantin X; Dubos-Arvis C; Otto J; Favier L; Avrillon V; Cadranel J; Moro-Sibilot D; Monnet I; Westeel V; Le Treut J; Brain E; Trédaniel J; Jaffro M; Collot S; Ferretti GR; Tiffon C; Mahier-Ait Oukhatar C; Blay JY
Ann Oncol; 2020 Feb; 31(2):289-294. PubMed ID: 31959346
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
32. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
[TBL] [Abstract][Full Text] [Related]
33. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm JC; Suvada J; Dunkel IJ; Casanova M; Zhang W; Ritchie N; Choi Y; Park J; Das Thakur M; Simko S; Wan Rachel Tam N; Ferrari A
Pediatr Blood Cancer; 2018 May; 65(5):e26947. PubMed ID: 29350463
[TBL] [Abstract][Full Text] [Related]
34. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
35. Safety of vemurafenib in patients with BRAF
Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
[TBL] [Abstract][Full Text] [Related]
36. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
[TBL] [Abstract][Full Text] [Related]
37. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
40. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]